Stifel initiated coverage on Inozyme Pharma Inc. INZY, saying, "This under-the-radar stock could be worth a look ahead of it." The company's lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in these molecules. It is currently in clinical development for ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis. In July, the FDA granted fast track designation ...